Advisory Board
Sebastian Stintzing, M.D
Germany
Sebastian Stintzing M.D., is Professor of Medicine and Head of the Division of Haematology, Oncology, and Tumor Immunology (CCM), Department of Medicine at Charité Universitaetsmedizin Berlin. His research focuses on predictive and prognostic biomarkers in the treatment of GI cancer with a special focus on colorectal cancer. He is a member of various national and international cancer associations and speaker of the steering committee of the working group of Colorectal Carcinoma of the German AIO. He coordinates several multicentre and international investigator initiated studies. He earned his Postdoctoral Lecture Qualification with a thesis on prognostic and predictive factors in the treatment of metastatic colorectal cancer.
“My main focus is to optimize the treatment for patients with GI malignancies. Clinical studies I coordinate usually compare approved substances against each other or evaluate them in untested sequences. Additionally, data and biomaterial from these studies are used for the development of clinical and molecular markers to further individualize our patients´ treatment. Arfolitixorin is a new substance which will hopefully increase the efficacy of the long established FOLFOX regimen without adding toxicity”.
Heinz Josef Lenz, M.D.
USA
Heinz Josef Lenz, M.D., FACP, is the Associate Director for Clinical Sciences, Professor of Medicine and Preventive Medicine and J.Terrence Lanni Chair for Cancer Research at the Keck School of Medicine, Norris Comprehensive Cancer Center of the University of Southern California. Dr Lenz is an active researcher and focuses on topics including the identification of novel targets, early drug development, regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, new methods of early detection, and better surveillance of these cancers and his laboratory has been long and continuously funded by NIH and NCI. He is a member of several professional societies, including the American Association for Cancer Research and the American Gastroenterology Association. Dr. Lenz is the author of over 430 peer-reviewed publications and invited papers, reviews, and editorials. He also serves as Chair of the Translational Medicine Committee in the SWOG GI Committee He is a member of the NCI Task Force for Gastroesophageal Cancer, the NCI Investigational Drug Committee and the NCI Translational Science Committee. During the past 20 years he has mentored 40 Postdoctoral Research Scholars, Oncology Fellows and 15 Pre-Med and Graduate Students.
“I am a physician-scientist known for my pioneering work on the pharmacogenomics of GI cancers and leading to the design of prospective trials using biomarkers we have identified in DNA repair, angiogenesis, immune pathways and EGFR signaling. We have amassed significant expertise in early drug development taking advantage of our extensive preclinical models with cancer organoids and PDX models. We have also incorporated our expertise in biomarkers such as single cell classification, Circulating Tumor Cells, ctDNA and molecular classification of colon cancer into clinical trial designs. I hope that the new substance arfolitixorin will improve outcomes for patients with metastatic colorectal cancer.”
Takayuki Yoshio, M.D
Japan
Takayuki Yoshino M.D., is the Director for the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East in Chiba, Japan, and Head of the Clinical Research Coordinating Division. Dr. Yoshino has a particular interest in chemotherapy for gastrointestinal cancers, especially for colorectal cancer, where he focuses on also on translational research regarding potential predictive and prognostic biomarkers. He has worked closely in the USA with several world-renowned institutions, including the Mayo Clinic, Dana-Farber Cancer Institute and the Vanderbilt-Ingram Cancer Center. Dr. Yoshino has had over 20 first or corresponding author publications on metastatic colorectal cancer including Lancet Oncology and The New England Journal of Medicine. Dr.Yoshino holds several professional appointments, serving on guideline member of the Japanese Society for Cancer of the Colon and Rectum, international guideline member of the European Society for Medical Oncology, and guideline member of the Japanese Society of Medical Oncology as well the administrative board for The Japanese Association for Molecular Target Therapy of Cancer.
“I am a leading Japanese specialist in the colorectal cancer field, particularly for clinical development of new agents as well as the translational research for investigating predictive & prognostic biomarkers and contributing to international programs. Arfolitixorin is a novel & promising compound with potential to increase the efficacy of the standard-of-care regimen without adding toxicity”.
Frits Peters, Ph.D.
Netherlands
Professor Frits Peters is professor emeritus at the Laboratory Medical Oncology, Amsterdam University Medical Center, professor at the Medical University of Gdansk, Poland, and honorary professor at Amity University in Noida, India.
The research of Frits Peters is focused on the development of new cancer treatments, from preclinical research to clinical phase I and II studies. He has been involved in several clinical studies of drug candidates that later gained market approvals for the treatment of cancer, such as gemcitabine, pemetrexed, S-1, TAS-102 and erlotinib. Notably, Frits Peters is recognized as a world leading expert on resistance and the pharmacology of chemotherapy and folate anticancer treatments.
Last updated: